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Abstract
Background: Several publications have focused on accompanying non-motor symptoms (NMS) in essential tremor (ET) patients; however, it remains unclear if
NMS are an intrinsic part of the disease or secondary phenomena. We present the results of several neuropsychiatric tests and their impact on quality of life (QoL) in
community-dwelling patients with ET.
Methods: Participants were recruited via a newspaper article about ET published in the local media and on the internet. All participants completed several
standard neuropsychiatric tests, including those that assess QoL. To compare differences between cases and controls, Student’s t-tests with Bonferroni-Holm post
hoc tests were performed. Spearman’s correlation coefficients were also calculated.
Results: We enrolled 110 patients with definite or probable ET. Highly significant changes were observed for apathy, anxiety, and cognition and negatively
impacted QoL. Most aberrations were independent of tremor severity and duration.
Discussion: The significant neuropsychiatric deficits and reduced QoL demonstrate a degree of illness that appears to be a non-motor phenotype rather than a
secondary effect of ET. In the future, NMS should carefully be explored in ET patients as they may have an impact on QoL and treatment.
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Introduction
Essential tremor (ET) is one of the most common movement
disorders with a well-known and clearly defined motor phenotype.1
Firstly described and understood as a monosymptomatic disease,2 our
understanding of ET symptomatology has shifted to a more complex
and multidimensional phenotype.3 ET pathology and the involved
central nervous regions are uncertain. There is some evidence that ET
could be a neurodegenerative disease4 with pathologic abnormalities
reported in the cerebellum5 and brain stem,6 but the results are
inconsistent, especially regarding Purkinje cell loss. Conversely, one
hypothesis is that ET is a functional disorder of subcortical circuits
without neurodegeneration.7 One factor common to these pathophy-
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siologic concepts is that they are not restricted to motor symptoms; there can
be additional symptoms besides the motor phenotype. In the last few years,
several publications have focused on accompanying non-motor symptoms
(NMS) with a variety of cognitive and neuropsychiatric changes in ET
patients. The reported abnormalities include mild cognitive impairment,8–10
apathy,11 depression,12,13 anxiety,14,15 sleep disturbances,16 and reduced
quality of life (QoL).17 It remains unclear if NMS are an intrinsic part of the
condition, as in Parkinson’s disease (PD) or Huntington’s disease, or if they
are secondary phenomena due to disease duration or severity. Most
published studies have focused on only one specific or a few NMS. Here we
attempted to define the pattern of NMS in ET and present the results of a
large variety of neuropsychiatric tests and their impact on QoL as a test
battery in ET patients recruited from the community.
Methods
Patient enrollment
Participants were recruited in a first step by an informative
newspaper article about ET published in the local media
(‘‘Mainpost,’’ 157,000 copies) and on the website of University
Hospital Wu¨rzburg, Germany. The article was combined with an
appeal to all readers who subjectively suffered from tremor to take part
in a neuropsychiatric study. After an initial contact by phone, all
interested individuals were invited to a screening and inclusion visit. In
preparation for the screening visit, the participants received a self-
questionnaire by mail. In total, 214 subjects completed the screening.
The study was approved by the Ethics Committee of the Wu¨rzburg
Medical Faculty and the Ethical Board of the Physician’s Association
Hessen and was conducted in accordance with the declaration of
Helsinki. All participants provided written, informed consent.
Neurological examination and tremor diagnosis
At the screening visit, all participants underwent medical history
taking and clinical examination by a movement disorder specialist
(T.M., A.P., or S.K.). ET was diagnosed as probable, possible, or
definite as defined by the consensus criteria of the Tremor
Investigation Group (TRIG).18 Tremor was quantified using the
Fahn-Tolosa-Marin Tremor Rating Scale (FTRS). To ensure the
quality of the data, the intra- and inter-rater reliabilities for
Archimedes spirals using intraclass coefficient were calculated.
Neuropsychiatric assessment
QoL with the Short-Form 36-Item Health Survey (SF-36). The Short-
Form 36-Item Health Survey (SF-36) was used to assess QoL. This is a
very common tool used to measure mental health and was validated in
a normal German population in a large survey.19,20 The SF-36 consists
of eight subdomains divided and grouped into a mental domain
(vitality, social function, role emotional, and mental health) and a
physical domain (physical function, role physical, bodily pain, and
general health). Each subdomain, as well a physical component score
(PCS) and mental component score (MCS), can be scored, with higher
scores indicating higher QoL.
Apathy Evaluation Scale (AES). To assess the clinical symptom of
apathy, defined as a lack of motivation and diminution of goal-directed
behavior, we used the validated and widely-used Apathy Evaluation
Scale (AES), which is an 18-item self-questionnaire that measures
apathy over the past 4 weeks.21 The total score ranges from 18 to 72
points, with higher values indicating more severe apathy. The mean
score of a healthy control group is 23.5 points (SD 5 5.8, n 5 37,
mean age 65.2 years).22
State-Trait Anxiety Scale (STAI-T). The State-Trait Anxiety Scale
(STAI-T) was used to measure the symptom anxiety as a characteristic
trait. We assessed ‘‘trait’’ anxiety by using items 21–40 of the original
test. Each item of the self-questionnaire can be rated on a 4-point
intensity scale. The mean values are adjusted for age and sex, and
higher values indicate more trait anxiety.23
Beck Depression Inventory (BDI). The Beck Depression Inventory
(BDI) is commonly used to measure depressive symptoms in the last
week and has been revised several times in the last few decades. The
current version consists of 21 items; the patient scores each from 0 to 3,
and the results are summed. Higher total scores indicate more severe
depressive symptoms. Validated cut-offs separate normal values from
severe depressive symptoms.24
Epworth Sleepiness Scale (ESS). To assess subjective daytime
sleepiness, we used the Epworth Sleepiness Scale (ESS) self-
questionnaire consisting of a depiction of eight situations that are
scored from 0 to 3. The sum scores have been validated in a German
cohort, with a normal value for healthy controls of 5.7 points (SD 5
3.0, n 5 159, mean age 35 years), and higher scores in patients with
various sleep disorders reflecting subjective sleep propensity.25
Frontal Assessment Battery (FAB). The Frontal Assessment Battery
(FAB) is a practicable and validated instrument to test executive
dysfunction and consists of six subtests (conceptualization, mental
flexibility, motor programming, sensitivity to interference, inhibitory
control, and environmental autonomy). For healthy controls, a mean
value of 17.3 points (SD 5 0.8, n 5 42) was reported in an English-
speaking control group, and lower scores indicate executive dysfunc-
tion.26 A trained rater (V.P. or S.K.) administered the FAB.
Parkinson Neuropsychometric Dementia Assessment (PANDA)
(cognitive subscore). The Parkinson Neuropsychometric Dementia
Assessment (PANDA) is a broadly used and validated instrument to
detect cognitive deficits; it was specially designed for subjects with
PD.27 It consists of five tasks including verbal fluency, word pair
association learning with immediate and delayed recall, visuospatial
perception, and working memory testing. There are validated cut-offs,
with scores lower than 18 points suspicious for mild cognitive
impairment and a mean score of 23.6 points (SD 5 5.4, n 5 108,
mean age 60.3 years) for healthy subjects.27 A trained rater (V.P. or
S.K.) administered the PANDA.
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Olfactory testing with Sniffin Sticks. Standardized Sniffin Sticks that
are commonly used in PD and other non-neurological disorders were
used to test olfactory function. The test is based on pen-like, odor-
dispensing devices, and we used the ‘‘Screening 12 Test’’ for odor
identification. The resulting values were compared to age-matched
values from a healthy control group to identify subjects with olfactory
dysfunction.28
Statistical analysis
In order to examine ET-induced QoL decreases, our findings were
compared to reference data from the German general population
(hereinafter referred to as ‘‘healthy controls’’) as provided in the
manuals of the questionnaires. The p-values and 95% confidence
intervals (CIs) for mean differences were computed using the Student’s
t-statistic. For SF-36 domains, STAI-T and Sniffin Sticks, we
employed age- and sex-specific German reference data; p , 0.05
was considered statistically significant. To account for multiple tests,
differences that remained significant after Bonferroni-Holm adjust-
ment are indicated. Relationships between age, tremor characteristics,
and NMS scores were assessed using Spearman’s correlation
coefficient r. All statistics were performed in SPSS (version 22).
Results
Epidemiology and clinical characteristics
Detailed patient characteristics are shown in Table 1. From the 214
patients at the screening visit, 110 patients (65 males) with definite or
probable ET were enrolled and completed the entire test battery (103
patients with definite ET; 7 patients with probable ET) (Figure 1). We
excluded 104 patients because they either did not fulfill the criteria for
probable or definite ET or suffered from other tremor conditions (i.e.,
parkinsonian, dystonic, psychogenic) (Figure 1). The intraclass
coefficients for intra- and inter-rater reliabilities for Archimedes spirals
ranged from 0.93–0.95. Regarding the topographical distribution of
tremor, all 110 (100%) patients displayed typical symmetric action
tremor of the upper extremities, 51 (46.4%) had an associated voice
tremor, 46 (41.8%) exhibited a head tremor, and 18 (16.4%) had an
action tremor of the lower extremities.
Neuropsychiatric and QoL scales
The results of the neuropsychiatric and QoL scales are summarized
in Table 2. The SF-36 results are graphically depicted in Figure 2, and
the AES, STAI-T, FAB, and PANDA scores are shown in Figure 3.
QoL measured by SF-36. Our group of ET patients showed no
significant differences in the PCS with 2.3 (CI 0.4, 4.2; p5 0.017) after
Bonferroni-Holm correction, but they did show a highly significant
reduction of 26.4 (CI 28.5, 24.3; p , 0.001) points in the MCS
compared with healthy, age-matched German controls. The sub-
analysis of the significant MCS domains showed maximum differences
in ‘‘role emotional’’ (p , 0.001) followed by ‘‘social function’’ (p ,
0.001) and ‘‘mental health’’ (p , 0.001). ‘‘Vitality’’ (p 5 0.006) showed
no significant change. Only the subdomains ‘‘social function’’ (r 5
20.27, p 5 0.005) and ‘‘mental health’’ (r 5 20.22, p 5 0.025)
correlated with the total FTRS score. ‘‘Role emotional’’ showed no
correlation with age, sex, age of onset (AOO), disease duration (DD),
or total FTRS score. Overall, MCS did not significantly correlate to
any attribute of the study population. For overall PCS, we found a
negative correlation with the total FTRS score.
AES. Compared to the normal control group, the mean total score in
AES was higher by 9.5 (CI 6.6, 12.5) points, with a mean score of 33.0.
This result was highly significant (p , 0.001), indicating more apathy
in ET patients. There was no correlation with age, sex, AOO, DD, or
total FTRS score.
STAI-T. The STAI-T in our study population was 39.8 and was
significantly higher by 3.7 points (CI 1.6, 5.9; p 5 0.001) compared to
a normal population adjusted for age and sex. This suggests more trait
anxiety in ET patients. There was no correlation with age, sex, AOO,
DD, or total FTRS score.
BDI. The BDI scores were 8.0 points in ET patients, with a difference
of 1.5 points (CI 20.2, 3.2) compared to a normal population.
However, this was not statistically significant (p 5 0.081).
Table 1. Clinical-demographic Data of 110 ET Cases1
Characteristics Cases
Age, y 65.2 ¡ 14.1
Sex, M 65 (59.1%)
Age of onset, y 41.4 ¡ 21.0
Disease duration, y 23.8 ¡ 16.4
FTRS score 36.8 ¡ 14.6







Upper extremities 110 (100%)
Voice 51 (46.4%)
Head 46 (41.8%)
Lower extremities 18 (16.4%)
1Values are presented as mean ¡ SD or number (%).
Abbreviations: ET, Essential Tremor; FTRS, Fahn-Tolosa-
Marin Tremor Rating Scale; M, Male; y, Years.
Non-motor Symptoms of Essential Tremor Musacchio T, Purrer V, Papagianni A, et al.
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services3
ESS. Regarding daytime sleepiness, we found a non-significant
difference of 0.9 points (CI 0.1, 1.7; p 5 0.021) after Bonferroni-
Holm correction. The total mean score in our population was 6.6.
FAB. Results of frontal cognitive dysfunction testing showed a highly
significant difference of21.1 points (CI21.5,20.7; p, 0.001), with a
mean score of 16.2 points in our study population. This was in the
normal range of healthy controls. There was a positive correlation with
age (r 5 20,41, p , 0.001) and AOO (r 5 20.25, p 5 0.009), but no
correlation with sex, DD, or total FTRS score.
PANDA-cognition. Compared to a normal population, the mean score
in our patients was 19.3 points, which corresponded to a highly
significant (p , 0.001) difference of 24.3 points (CI 25.8, 22.9)
indicating a tendency to mild cognitive impairment. Correlations were
found regarding age (r 5 20.30, p 5 0.002), AOO (r 5 20.21 p 5
0.029), and total FTRS score (r 5 20.39, p , 0.001).
Sniffin Sticks. Adjusted to age, there was no statistically significant
difference between the results in ET patients and the normal
population data. We observed a small absolute reduction of 20.3
points (p 5 0.139).
Test battery correlation analysis. Analyzing the Spearman correla-
tions among the tests themselves indicated that similar measures
were highly correlated; thus, this can be used as a quality indi-
cator for the reliability of our assessment technique. The highest
correlation coefficients were found between MCS/STAI-T
(r 5 0.78, p , 0.001), BDI/STAI-T (r 5 0.70, p , 0.001), AES/
STAI-T (r 5 0.62, p , 0.001), and AES/BDI (r 5 0.60, p , 0.001).
AES itself correlated with ESS (r 5 0.33, p 5 0.001) and PANDA
(r 5 20.34, p , 0.001), and PANDA-cognition and FAB were also
significantly correlated (r5 0.42, p, 0.001). All of these correlations
are listed in Table 3.
Discussion
Reports in the few last years have described NMS in patients
suffering from ET. There are additional features accompanying the
disease besides pure motor abnormalities.29 Most investigations
published to date have focused on isolated symptoms including
neuropsychiatric abnormalities (e.g., cognitive impairment30 and
depression13,14) and QoL.17 Another interesting and persistent
question is whether NMS in ET are a primary disease feature or
secondary reactive symptoms.31 Most investigations have been unable
to answer this question because either the study population was
relatively small12,32 or the NMS correlated with tremor severity or
duration.13 Another important limitation in most previous studies was
subject recruitment, which mainly occurred among outpatients in
specialized movement disorder units, and a consecutive selection
Figure 1. Flowchart Depicting the Diagnosis of All Recruited Participants
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bias.17 In the present study, patients were recruited using an
informative newspaper article in the local media, thereby producing
a study population that consisted mainly of patients who had never
sought specialist care. The epidemiologic data of our 110 participants
with definite and probable ET are in accordance with previous
publications regarding motor symptoms, tremor localization, age,
alcohol sensitivity, positive family history, AAO, and DD.33
The applied test battery identified a pattern of neuropsychiatric
findings and QoL changes. We were able to reveal that ET patients
experience higher apathy and trait anxiety and exhibit a measurably
impaired cognitive function. Regarding QoL measured with the SF-
36, we found a statistically significant difference in three out of four
MCS subdomains compared to a normal German population; these
findings are similar to those reported by Lorenz et al.17 Regarding the
Table 2. Non-motor Parameters among Patients with ET and Controls





n Mean SD n Mean SD
SF-36 domain
Physical3,5
Physical function 110 75.4 23.1 2886 85.7 22.1 2.4 21.8 6.6 0.25
Role physical 110 63.9 40.4 2856 83.7 31.7 29.2 216.9 21.4 0.021
Bodily pain 110 69.7 27.6 2905 79.1 27.4 21.6 26.7 3.5 0.53
General health 110 61.0 18.1 2859 68.1 20.2 1.0 22.5 4.6 0.57
PCS4,6 110 46.2 10.3 2773 50.2 10.2 2.3 0.4 4.2 0.017
Mental3,5
Vitality 110 54.7 17.6 2876 63.3 18.5 24.8 28.2 21.4 0.006
Social function 110 75.9 24.4 2911 88.8 18.4 210.2 214.9 25.6 ,0.0012
Role emotional 110 70.6 40.6 2855 90.4 25.6 216.6 224.3 28.9 ,0.0012
Mental health 110 63.9 18.7 2871 73.9 16.4 210.2 213.7 26.7 ,0.0012
MCS4,6 110 45.9 11.1 2773 51.5 8.1 26.4 28.5 24.3 ,0.0012
AES 110 33.0 8.3 37 23.5 5.8 9.5 6.6 12.5 ,0.0012
STAI-T5 110 39.8 11.3 2385 35.8 9,5 3.7 1.6 5.9 0.0012
BDI 110 8.0 6.5 86 6.5 5.2 1.5 20.2 3.2 0.081
ESS 110 6.6 3.4 159 5.7 3.0 0.9 0.1 1.7 0.021
FAB 110 16.2 1.8 42 17.3 0.8 21.1 21.5 20.7 ,0.0012
PANDA-cognition 110 19.3 5.6 108 23.6 5.4 24.3 25.8 22.9 ,0.0012
Sniffin Sticks6 110 8.8 2.3 1012 10.2 2.1 20.3 20.7 0.1 0.139
Abbreviations: AES, Apathy Evaluation Score; BDI, Beck Depression Inventory; ESS, Epworth Sleepiness Scale; ET, Essential Tremor; FAB,
Frontal Assessment Battery; MCS, Mental Component Score; PANDA, Parkinson Neuropsychometric Dementia Assessment; PCS, Physical
Component Score; SD, Standard Deviation; SF-36, Short-Form 36-Item Health Survey; STAI-T, State-Trait Anxiety Scale.
1For details of the control subjects refer to the methods and literature.
2Remains significant after Bonferroni-Holm adjustment (multiple testing).
3Transformed scores.
4Normalized scores.
5Stratified by age and sex.
6Stratified by age.
7Compared using Student’s t-tests.
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‘‘role emotional’’ subdomain of the MCS, there was no correlation
with tremor severity measured by FTRS and tremor duration. For
‘‘mental health’’ and ‘‘social function,’’ we found weak correlations
with FTRS but no correlation with tremor duration. This is in contrast
to the greater changes in absolute values of all subdomains reported by
Lorenz et al.17 This could be an effect of the possible selection bias due
to the use of outpatients as a study population. Hypothetically, these
patients actively seek specialist care because they suffer more from
their motor symptoms than the average ET patient. The PCS showed
a weak negative correlation with disease severity; however, we did not
observe any significant differences in PCS or its subdomains between
ET patients and controls. The MCS and PCS findings suggest that
reduced QoL in ET patients is mainly caused by mental factors rather
than physical impairment and might be classified as intrinsic NMS of
ET.
Apathy was the major neuropsychiatric symptom in our sample of
ET patients; this symptom is observed in a wide spectrum of
psychiatric disorders (e.g., depression or personality disorders) but is
also an NMS in movement disorders like PD.34 In line with the study
by Louis et al.,11 we observed a highly significant increase in the AES
score but could not find a correlation with tremor severity or DD. It
could be hypothesized that apathy is even more distinct in ET because
patients with severe apathy might not have responded to our
recruitment method. Another highly significant aberration was
observed in trait anxiety independent of tremor characteristics,
especially tremor severity. In the past, anxiety in tremor patients
correlated with functional disability.32 In two other studies of
Turkish15 and Asian35 cohorts, anxiety was reported as a concomitant
symptom of ET. Interestingly, although apathy and trait anxiety can
be clinical symptoms of depression, we did not find a significant
change in BDI. This contrasts with the small study by Lacritz et al.13
conducted with only 13 ET patients. Studies with larger cohorts15,36
reported significant changes in depressive mood scores using scales
other than the BDI, which makes comparison difficult. We found a
significant correlation of BDI scores with AES, ESS, and STAI-T
scores, likely due to the fact that the BDI subitems measure apathy,
anxiety, and sleep irregularities. These correlations underscore the
quality and reliability of our results. Regarding cognitive impairment,
several authors have reported that there are cognitive deficits in ET in
several cognitive subdomains.8,12,37,38 The available studies differ
greatly in the numbers of assessed patients, and the age distribution of
the cohort also plays an important role. In our mixed study population,
we found a highly significant decline in the FAB test battery; this is
similar to former studies measuring frontal executive function in ET
patients.38–40 However, the mean FAB value in our study was within
the normal range of healthy controls, and the significant difference of
one point in our sample probably has no clinical impact. To our
knowledge, we are the first to use the PANDA-cognition test to assess
ET patients. We found a significant decrease with a marginally higher
mean value toward the cut-off for mild cognitive dysfunction, and this
correlated with tremor severity as measured by FTRS-score. Dementia
in PD is considered to be subcortical and thereby also consists of
frontal executive dysfunction that can be measured with the PANDA.
Because all of our abnormal findings (apathy, anxiety, and frontal
Figure 2. Means and SDs of Patients with ET and Controls on SF-36
Subdomains. Significant after Bonferroni-Holm correction. * p , 0.001. ET,
Essential Tremor; SD, Standard Deviation; SF-36, Short-Form 36-Item Health
Survey.
Figure 3. Means and SDs of Patients with ET and Controls on the AES,
STAI-T, FAB, and PANDA. Significance after Bonferroni-Holm correction.
* p # 0.001. AES, Apathy Evaluation Scale; ET, Essential Tremor; FAB, Frontal
Assessment Battery; PANDA, Parkinson Neuropsychometric Dementia Assessment;
SD, Standard Deviation; STAI-T, State-Trait Anxiety Trait.
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executive function) converge anatomically to frontotemporal and
mesolimbic structures, imaging studies should be performed to assess
these brain regions in ET.
We did not observe a significant difference in daytime sleepiness
between subjects with ET and data from normative controls, which is
in accordance with several previous studies that administered the ESS
to ET patients.14,39 Contrary to previous reports,40 olfactory testing
did not reveal any significant aberrations suggesting that ET is not
characterized by olfactory system neurodegeneration.
This study has some limitations that have to be pointed out, most
notably the absence of a control group. Instead, we compared the ET
data with standardized psychometric measurements and think this is
applicable because there was no intervention and the data were
collected at a single time point. Nevertheless, it would be useful to
include a control group in subsequent studies to verify our results.
Additionally, further longitudinal investigations dealing with NMS in
ET should be designed to observe changes over time. Our recruitment
method could be limited by selection bias (e.g., only more interested or
well-educated patients could have answered the newspaper article), but
we consider that it was more appropriate than clinic-based sampling.
Another interesting topic to pursue would be subgroup analysis (e.g.,
sex, distribution of tremor, medication). Our sex-specific subgroup
analysis did not reveal a significant difference between male and
female participants (data not shown). Therefore, a larger cohort would
be more appropriate for future subgroup analyses.
In conclusion, we identified a pattern of NMS in ET using a broad
battery of neuropsychiatric and QoL tests in a community setting. The
reported epidemiologic and clinical findings of ET symptoms seem to
be representative for the known disease phenotype. In our view, the
significant neuropsychiatric deficits (apathy, anxiety, frontal executive
dysfunction) and reduced QoL of ET patients themselves demonstrate
a degree of illness that may be regarded as a non-motor phenotype
rather than a secondary effect of motor symptoms. While our results
are not clinically obvious, these deficits could be part of a psychiatric
premorbid condition. In the future, NMS should be carefully explored
in ET patients because they might affect QoL and treatment.
Longitudinal studies are required to clarify the non-motor phenotype
in ET and learn more about the development and course of the
reported abnormalities.
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